Premium
Marking‐to‐Market: Panacea or Pandora's Box?
Author(s) -
PLANTIN GUILLAUME,
SAPRA HARESH,
SHIN HYUN SONG
Publication year - 2008
Publication title -
journal of accounting research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.767
H-Index - 141
eISSN - 1475-679X
pISSN - 0021-8456
DOI - 10.1111/j.1475-679x.2008.00281.x
Subject(s) - panacea (medicine) , balance sheet , construct (python library) , business , value (mathematics) , accounting , historical cost , economics , finance , fair value , medicine , alternative medicine , pathology , machine learning , computer science , programming language
Financial institutions have been at the forefront of the debate on the controversial shift in international standards from historical cost accounting to mark‐to‐market accounting. We show that the trade‐offs at stake in this debate are far from one‐sided. While the historical cost regime leads to some inefficiencies, marking‐to‐market may lead to other types of inefficiencies by injecting artificial risk that degrades the information value of prices, and induces suboptimal real decisions. We construct a framework that can weigh the pros and cons. We find that the damage done by marking‐to‐market is greatest when claims are (1) long–lived, (2) illiquid, and (3) senior. These are precisely the attributes of the key balance sheet items of banks and insurance companies. Our results therefore shed light on why banks and insurance companies have been the most vocal opponents of the shift to marking‐to‐market.